Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis.

Authors:
Alexei Christodoulides Bradley N Bohnstedt

eNeurologicalSci 2022 Sep 17;28:100412. Epub 2022 Jun 17.

Department of Neurological Surgery, Indiana University - School of Medicine, Indianapolis, IN, United States of America.

Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs promises to offer numerous patient benefits. We aimed to examine the efficacy of Factor Xa inhibitors in comparison to warfarin in the long-term treatment of CVSTs. A single-center retrospective analysis was conducted in which 49 eligible patients having presented with a first-time CVST were identified. Long-term anticoagulation was achieved with Warfarin (n = 23) or Factor Xa Inhibitors (n = 26; Apixaban or Rivaroxaban). Outcomes of interest were improvements in patient functional status, modified Ranking Scores (mRS), and radiographic improvement/resolution in sinus thromboses. Secondary comparisons included complication rates, particularly recurring venous thrombotic events. Patient mRS scores by 7-to-18-month follow-up all fell within the extremely favorable range of 0-1 regardless of the long-term anticoagulant (P-value = 0.3591). Proportion of patients with radiographic improvement/resolution of thrombosed sinuses trended towards being higher in the Factor Xa Inhibitor group at the <12-month period, 69.2%, compared to 33.3% with Warfarin (-value = 0.0548). By the >12-month follow-up period, Warfarin and Factor Xa inhibitor groups had similar rates of radiographic sinus improvement - 76.9% versus 71.4%, respectively (-value = 0.6298). No statistically significant differences were documented between groups regarding complications. Factor Xa inhibitors are equally as effective as Warfarin in the long-term treatment of CVSTs, whether it be restoring patient functional status, sinus thrombus burden reduction, or minimizing bleeding complications whilst preventing recurrent venous thrombosis.

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ensci.2022.100412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234611PMC
September 2022

Publication Analysis

Top Keywords

factor inhibitors
20
long-term treatment
12
sinus thrombosis
8
radiographic improvement/resolution
8
factor inhibitor
8
treatment cvsts
8
warfarin long-term
8
long-term anticoagulation
8
patient functional
8
functional status
8
treatment cerebral
8
retrospective analysis
8
cerebral venous
8
single-center retrospective
8
venous sinus
8
factor
7
warfarin
6
long-term
6
sinus
5
inhibitors
5

Keyword Occurance

Similar Publications

The Effect of Capsaicin on Neuroinflammatory Mediators of Rosacea.

Authors:
Hyeon Bin Kim Eui Young Na Sook Jung Yun Jee-Bum Lee

Ann Dermatol 2022 Aug;34(4):261-269

Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea.

Background: Rosacea is a chronic inflammatory skin disease with a pathophysiological mechanism that remains unclear. Recently, dysregulation of the sensory nerve system has been implicated in the development of this condition.

Objective: This study aimed to investigate the effect of capsaicin on neuroinflammatory mediators in rosacea. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.

Authors:
Matteo Santoni Javier Molina-Cerrillo Zin W Myint Francesco Massari Tomas Buchler Sebastiano Buti Marc R Matrana Ugo De Giorgi Mimma Rizzo Ignacio Ortego Zabalza Luca Galli Paolo Andrea Zucali Gaetano Aurilio Lorena Incorvaia Maria Bassanelli Giulia Mammone Alessia Salfi Luca Isella Veronica Mollica Enrique Grande Camillo Porta Nicola Battelli

Target Oncol 2022 Aug 10. Epub 2022 Aug 10.

Oncology Unit, Macerata Hospital, Macerata, Italy.

Background: Drug-drug interactions are a major concern in oncology and may potentially affect the outcome of patients with cancer.

Objective: In this study, we aimed to determine whether the concomitant use of statins, metformin, or proton pump inhibitors affects survival in patients with metastatic renal cell carcinoma treated with first-line combination therapies.

Methods: Medical records of patients with documented metastatic renal cell carcinoma between January 2016 and November 2021 were reviewed at 17 participating centers. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.

Authors:
Pei Ma Ruohan Huang Yunru Gu Yuan Fang Xi Wu Dong-Sheng Chen Han-Wu Zhang Wen Gao Yongqian Shu

Anticancer Drugs 2022 Aug 10. Epub 2022 Aug 10.

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University and.

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved response in all stages of patients with EGFR positive mutations in nonsmall cell lung cancer. However, the primary resistance mechanism of EGFR-TKIs has not been thoroughly revealed. Here, we described a case of a 64-year-old male with lung adenocarcinoma presented primary resistance on osimertinib combined with bevacizumab and platinum-based chemotherapy, next-generation sequencing revealed EGFR exon 21 L858R mutation and MET gene amplification. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report.

Authors:
Daoan Cheng Shuxian Tang Dong Li Weiqing Zhao Wei Wei Cheng Fang Mei Ji

Anticancer Drugs 2022 Aug 9. Epub 2022 Aug 9.

Departments of Oncology, the Third Affiliated Hospital of Soochow University, Changzhou, China.

Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non-small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient after osimertinib resistance who was successfully treated by high-dose furmonertinib (AST2818) at 160 mg. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Epidermal growth factor receptor mutation p.A864V in small cell lung cancer and lung squamous cell carcinoma: a case report and review of literature.

Authors:
Wusheng Deng Gang Chen Dandan Xiong Rongquan He Ke Wang Huasong Lu Jinliang Kong

Anticancer Drugs 2022 Aug 9. Epub 2022 Aug 9.

Department ofPathology The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Mutations in the epidermal growth factor receptor (EGFR) have been identified in 10-20% of nonsmall cell lung cancer (NSCLC), specifically lung adenocarcinomas. However, these mutations have rarely been reported in small cell lung cancer (SCLC) and lung squamous cell carcinoma (LUSC). Treatment for SCLC and LUSC patients has not yet been established. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}